Table 1.

Summary of phospho-eIF4E staining in the 6 evaluable patients in the pharmacodynamic study

Patient	Baseline phospho-eIF4E, %	Posttreatment phospho-eIF4E, %
1	70	30
2	90	30
3	70–80	40–50
4	40	40
5	80	50
6	80	80

Results are scored as the percent of tumor cells that had positive nuclear and/or cytoplasmic phosho-eIF4E staining by immunohistochemistry. Samples from subjects 3 and 4 were surgical specimens; the remainder were fine-needle aspirates